EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future

Andrea Duminuco iD, Antonella Nardo, Gaetano Giuffrida, Salvatore Leotta iD, Uros Markovic iD, Cesarina Giallongo, Daniele Tibullo iD, Alessandra Romano iD, Francesco Di Raimondo, Giuseppe A Palumbo iD

Journal of Clinical Medicine · 11.03.2023 · 12 (6) · 2188

DOI: 10.3390/jcm12062188 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.03.2023. Verfasst von Andrea Duminuco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit with BMT, A.O.U. Policlinico "G. Rodolico-San Marco", Via S. Sofia 78, 95123 Catania, Italy. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among the myeloproliferative diseases, myelofibrosis is a widely heterogeneous entity characterized by a highly variable prognosis. In this context, several prognostic models have been proposed to categorize these patients appropriately. Identifying who deserves more invasive treatments, such as bone marrow transplantation, is a critical clinical need. Age, complete blood count (above all, hemoglobin value), constitutional symptoms, driver mutations, and blast cells have always represented the milestones of the leading models still used worldwide (IPSS, DIPSS, MYSEC-PM). Recently, the advent of new diagnostic techniques (among all, next-generation sequencing) and the extensive use of JAK inhibitor drugs have allowed the development and validation of new models (MIPSS-70 and version 2.0, GIPSS, RR6), which are continuously updated. Finally, the new frontier of artificial intelligence promises to build models capable of drawing an overall survival perspective for each patient. This review aims to collect and summarize the existing standard prognostic models in myelofibrosis and examine the setting where each of these finds its best application.

Schlagwörter

Stichwörter der Autor:innen

myelofibrosisoverall survivalprognosisprognostic scorerisk category

Autor:innen und Institutionen

  • Hematology Unit with BMT, A.O.U. Policlinico "G. Rodolico-San Marco", Via S. Sofia 78, 95123 Catania, Italy.
  • Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.
  • Dipartimento di Scienze Biomediche e Biotecnologiche, University of Catania, 95123 Catania, Italy.
  • Dipartimento di Specialità Medico-Chirurgiche, CHIRMED, Sezione di Ematologia, University of Catania, 95123 Catania, Italy.

ORCID-Profile: Andrea Duminuco, Salvatore Leotta, Uros Markovic, Daniele Tibullo, Alessandra Romano, Giuseppe A Palumbo

Zitieren

APA

Duminuco, A., Nardo, A., Giuffrida, G., Leotta, S., Markovic, U., Giallongo, C., Tibullo, D., Romano, A., Di Raimondo, F., & Palumbo, G. A. (2023). Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future. Journal of Clinical Medicine, 12(6), 2188. https://doi.org/10.3390/jcm12062188

Vancouver

Duminuco A, Nardo A, Giuffrida G, Leotta S, Markovic U, Giallongo C, et al. Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future. Journal of Clinical Medicine. 2023;12(6):2188. doi:10.3390/jcm12062188

BibTeX
@article{Duminuco2023,
  author = {Duminuco, Andrea and Nardo, Antonella and Giuffrida, Gaetano and Leotta, Salvatore and Markovic, Uros and Giallongo, Cesarina and Tibullo, Daniele and Romano, Alessandra and Di Raimondo, Francesco and Palumbo, Giuseppe A},
  title = {Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {6},
  pages = {2188},
  doi = {10.3390/jcm12062188}
}
Kostenlos starten →